Autobio(SH:603658) Sou Hu Cai Jing·2025-08-07 11:27Group 1 - The core viewpoint of the articles highlights the performance and valuation of Antu Biology, which closed at 41.23 yuan, up 2.77%, with a rolling PE ratio of 20.66, marking a new low in 77 days, and a total market capitalization of 23.56 billion yuan [1][2] - Antu Biology ranks 45th in the medical device industry, which has an average PE ratio of 54.79 and a median of 37.86 [1][2] - As of March 31, 2025, Antu Biology has 34,163 shareholders, an increase of 3,382 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The main business of Antu Biology includes research, manufacturing, integration, and services of in vitro diagnostic reagents and instruments, with key products being immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - Antu Biology was included in the "2023 Annual List of China's Top 100 Pharmaceutical Companies" and achieved second place in the "2023 Annual R&D Index Top 100 List of Chinese Pharmaceutical Enterprises" due to its outstanding performance in R&D results and support indices [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76%, with a gross profit margin of 65.07% [1]